NCT04278898RecruitingPhase 2
Targeting the Neurobiology of RRB in Autism Using N-acetylcysteine: Single-dose
Targeting the Neurobiology of Restricted and Repetitive Behaviors in Children With Autism Using N-acetylcysteine: a Single-dose Challenge Study
Source: ClinicalTrials.gov · Last updated 15 May 2026
Brief summary (registry, in English)
The goal of this study is to target the neurobiology of restricted and repetitive behaviors in children with autism spectrum disorder using N-acetylcysteine (NAC), a well-tolerated nutritional supplement that has shown promise for reducing symptom severity in recent small-scale trials. The findings from this research will shed light on the mechanisms of action underlying the clinical benefits of NAC.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 24 (estimated)
- First submitted
- 18 Feb 2020
- Start date
- 12 Feb 2021
- Primary completion date
- 31 Jul 2028
- Lead sponsor
- Stanford University
- Diseases
- Autism
- NCT number
- NCT04278898
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 24
- From 12 Feb 2021 to the primary completion date, 31 Jul 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- presence of known genetic abnormalities associated with Autism Spectrum Disorder (e.g. Fragile X),
- current or life-time diagnosis of severe psychiatric disorder (e.g., schizophrenia),
Other
- presence of significant medical problems that would interfere with participation,
- the inability of at least one caregiver to speak/read English to a sufficient level to complete study requirements and materials,
- individuals taking antioxidant agents and glutathione prodrugs, or
- the inability/unwillingness to swallow an agent during the screening visit.
Who the study is looking for
- children between 3 years and 12 years 11 months at the time of consent
- diagnosis of Autism Spectrum Disorder confirmed with the Autism Diagnostic Interview-Revised (ADI-R) and the Autism Diagnostic Observation Schedule-2 (ADOS-2), or Brief Observation of Symptoms of Autism (BOSA), or Childhood Autism Rating Scale- Second Edition (CARS-2).
- at least moderate Restricted and Repetitive Behaviors severity defined by a Children's Yale-Brown Obsessive Compulsive Scale for children with autism spectrum disorder score ≥ 11,
- physical development indicative of prepubescence as defined by the criteria for Tanner Stage 1,
- medically stable,
- passes MR safety screening (e.g., no metal in the body).
Age in the registry: 3 years to 12 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Stanford University School of Medicine Coordinator of this site? Confirm its status | Stanford | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.